{"id":15640,"date":"2019-10-09T22:17:30","date_gmt":"2019-10-09T20:17:30","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=15640"},"modified":"2019-10-15T22:21:24","modified_gmt":"2019-10-15T20:21:24","slug":"bluebird-bio-and-novo-nordisk-enter-into-research-agreement","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/","title":{"rendered":"bluebird bio and Novo Nordisk Enter into Research Agreement"},"content":{"rendered":"\n

bluebird bio and\u00a0Novo Nordisk have entered into a research collaboration to jointly develop next-generation\u00a0in vivo\u00a0<\/em>genomeediting<\/g> treatments for genetic diseases, including haemophilia<\/g>. During the three-year research collaboration, bluebird and\u00a0Novo Nordisk\u00a0will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia<\/g> A a lifetime free of factor replacement therapy.<\/p>\n\n\n\n

The research collaboration will utilise bluebird bio\u2019s proprietary mRNA-based megaTAL\u2122 technology that has the potential to provide a highly specific and efficient way to silence, edit or insert genetic components. Aligned with Novo Nordisk\u2019s haemophilia portfolio, the research collaboration will initially focus on correcting FVIII-clotting factor deficiency, with the potential to explore additional therapeutic targets.<\/p>\n\n\n\n

\u201cWe are pleased to announce our collaboration with bluebird whose demonstrated capabilities in gene therapy will enable the next-generation of innovative products to make a significant impact on patients\u2019 lives,\u201d said Marcus Schindler, senior vice president for Global Drug Discovery at Novo Nordisk. \u201cThis important research collaboration aimed at addressing genetic diseases at the DNA level reflects Novo Nordisk\u2019s enduring commitment and dedication to inventing disease-modifying medicines that can truly change the lives of people living with haemophilia and other genetic diseases.\u201d<\/p>\n\n\n\n

\u201cbluebird has made tremendous progress on enabling an\u00a0in vivo<\/em>\u00a0gene editing platform based on our megaTAL technology, including important advances in high-quality mRNA production and purification,\u201d said\u00a0Philip Gregory, D. Phil., chief scientific officer, bluebird bio. \u201cWe believe this technology has the potential to create a highly differentiated approach to the treatment of many severe genetic diseases. Moreover, we are thrilled to be able to combine this new platform technology with Novo Nordisk\u2019s deep expertise in haemophilia research and therapeutics. We believe this collaboration will move us toward our shared goal of recoding the treatment paradigm and substantially reduce the burden of diseasefor patients with factor VIII deficiency.\u201d<\/p>\n\n\n\n

Source: bluebird bio<\/a> (press release)<\/p>\n","protected":false},"excerpt":{"rendered":"

bluebird bio and\u00a0Novo Nordisk have entered into a research collaboration to jointly develop next-generation\u00a0in vivo\u00a0genomeediting treatments for genetic diseases, including haemophilia. During the three-year research collaboration, bluebird and\u00a0Novo Nordisk\u00a0will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia A a lifetime free of factor replacement therapy. The research […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-15640","post","type-post","status-publish","format-standard","hentry","category-gezondheid"],"acf":[],"yoast_head":"\nbluebird bio and Novo Nordisk Enter into Research Agreement - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bluebird bio and Novo Nordisk Enter into Research Agreement - hollandbio\" \/>\n<meta property=\"og:description\" content=\"bluebird bio and\u00a0Novo Nordisk have entered into a research collaboration to jointly develop next-generation\u00a0in vivo\u00a0genomeediting treatments for genetic diseases, including haemophilia. During the three-year research collaboration, bluebird and\u00a0Novo Nordisk\u00a0will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia A a lifetime free of factor replacement therapy. The research […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-09T20:17:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-10-15T20:21:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"bluebird bio and Novo Nordisk Enter into Research Agreement\",\"datePublished\":\"2019-10-09T20:17:30+00:00\",\"dateModified\":\"2019-10-15T20:21:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/\"},\"wordCount\":324,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/\",\"name\":\"bluebird bio and Novo Nordisk Enter into Research Agreement - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-10-09T20:17:30+00:00\",\"dateModified\":\"2019-10-15T20:21:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bluebird bio and Novo Nordisk Enter into Research Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bluebird bio and Novo Nordisk Enter into Research Agreement - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/","og_locale":"en_US","og_type":"article","og_title":"bluebird bio and Novo Nordisk Enter into Research Agreement - hollandbio","og_description":"bluebird bio and\u00a0Novo Nordisk have entered into a research collaboration to jointly develop next-generation\u00a0in vivo\u00a0genomeediting treatments for genetic diseases, including haemophilia. During the three-year research collaboration, bluebird and\u00a0Novo Nordisk\u00a0will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia A a lifetime free of factor replacement therapy. The research […]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/","og_site_name":"hollandbio","article_published_time":"2019-10-09T20:17:30+00:00","article_modified_time":"2019-10-15T20:21:24+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"bluebird bio and Novo Nordisk Enter into Research Agreement","datePublished":"2019-10-09T20:17:30+00:00","dateModified":"2019-10-15T20:21:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/"},"wordCount":324,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/","name":"bluebird bio and Novo Nordisk Enter into Research Agreement - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-10-09T20:17:30+00:00","dateModified":"2019-10-15T20:21:24+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/bluebird-bio-and-novo-nordisk-enter-into-research-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"bluebird bio and Novo Nordisk Enter into Research Agreement"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=15640"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15640\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=15640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=15640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=15640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}